罕见血友病因素市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

罕见血友病因子市场按治疗(因子浓缩物、新鲜冷冻血浆、冷沉淀物等)和地理划分

市场快照

RHF_Image 1
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

推动市场增长的某些因素包括越来越多的采用和批准新的治疗技术、越来越多的政府举措和资金。

同样,根据 2019 年全球血友病护理报告,全球有超过 1,125,000 名男性患有遗传性出血性疾病,其中 418,000 名患有最严重的未确诊疾病。据估计,全球约有 400,000 人患有血友病。

科学家们报告说,血友病在全世界男性中的患病率是以前认为的三倍,并且仍然与较差的预期寿命有关,尤其是在低收入国家。因此,血友病的增加与稀有血友病因子市场需求的增加有关。

报告范围

根据报告的范围,血友病是一种遗传性出血性疾病,可阻止血液正常凝结。主要症状是不受控制的,通常是身体不同部位的自发性出血。称为罕见凝血障碍 (RCD) 的纤维蛋白原、凝血酶原、因子 V (FV)、FVII、FVIII、FIX、FX、FXI 和 FXIII 的缺乏可能导致凝血障碍,导致自发性或创伤后和术后出血。

By Treatment
Factor Concentrate
Fresh frozen plasma (FFP)
Cryoprecipitate
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

新鲜冷冻血浆 (FFP) 有望在治疗领域占据重要市场份额

血浆输注适用于需要更换多种凝血因子的患者在紧急侵入性手术前控制出血或预防出血。新鲜冷冻血浆是在指定时间范围内(通常在 8 小时内)冷冻的单位全血的液体部分。FFP 含有除血小板以外的所有凝血因子。FFP 含有纤维蛋白原(400 至 900 毫克/单位)、白蛋白、蛋白 C、蛋白 S、抗凝血酶、组织因子途径抑制剂。FFP 只能静脉注射。FFP 必须与接受者的红细胞 ABO 兼容。目测 FFP 容器和液体应无渗漏、凝块或异常颜色。

hemophilia.png

北美在市场上占主导地位,预计在预测期内也会如此

根据疾病控制和预防中心 (CDC) 的数据,每 5,000 名活产男性中就有 1 名患有 A 型血友病。A 型血友病的发病率约为 B 型血友病的四倍。据估计,美国血友病患者人数约为 20,000 人(国家血友病基金会,2018 年)。

在美国,大多数血友病患者在很小的时候就被诊断出来。根据 CDC 数据,轻度血友病患者的中位诊断年龄为 36 个月,中度血友病患者为 8 个月,重度血友病患者为 1 个月。在大约三分之二的病例中,有血友病家族史。血友病的诊断是通过特殊的血液检测进行的,大多数婴儿可以在出生后不久进行检测。有时会进行产前基因检测以在出生前诊断血友病(CDC,2019)。

Rare Hemophilia Factors Market - Growth Rate by Region - Image

竞争格局

全球罕见血友病因素市场竞争适度,由许多主要参与者组成。Baxter Healthcare、Bayer Healthcare、Bio Products Laboratory Ltd.、Biogen、CSL Behring、Novo Nordisk、Pfizer, Inc.、Takeda Pharmaceutical Co. Ltd. 等公司在稀有血友病因子市场占有相当大的市场份额。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Adoption and Approval of New Treatment Techniques

      2. 4.2.2 Growing Number of Government Initiatives and Funding

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment

      1. 5.1.1 Factor Concentrate

      2. 5.1.2 Fresh frozen plasma (FFP)

      3. 5.1.3 Cryoprecipitate

      4. 5.1.4 Others

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Baxter International Inc.

      2. 6.1.2 Bayer AG

      3. 6.1.3 Bio Products Laboratory Ltd.

      4. 6.1.4 Biogen Inc.

      5. 6.1.5 CSL Behring

      6. 6.1.6 Novo Nordisk A/S

      7. 6.1.7 Pfizer, Inc.

      8. 6.1.8 Takeda Pharmaceutical Co. Ltd.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Rare Hemophilia Factors Market market is studied from 2018 - 2026.

The Rare Hemophilia Factors Market is growing at a CAGR of 4.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Novo Nordisk, Bayer AG, Pfizer, Inc., Takeda Pharmaceutical Co. Ltd., Sanofi S.A. are the major companies operating in Rare Hemophilia Factors Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!